C-Reactive Protein-Triglyceride-Glucose Index (CTI) is an Independent Predictor of Cardiovascular Mortality in Patients with Metabolic Syndrome

No abstract is available for this paper.

• Publication year

  2026

• Venue

  Journal of Clinical Lipidology

• Publication date

  2026-03-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.jacl.2026.02.026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The association between novel metabolic parameters and all-cause/cardiovascular mortality in patients with metabolic syndrome is modified by age

  2025cited by this paper
• Association of C reactive protein triglyceride glucose index with mortality in coronary heart disease and type 2 diabetes from NHANES data

  2025cited by this paper
• Association between C-reactive protein-triglyceride glucose index and stroke risk in different glycemic status: insights from the China Health and Retirement Longitudinal Study (CHARLS)

  2025cited by this paper
• Association of weight-adjusted waist index with cardiovascular disease and mortality among metabolic syndrome population

  2024cited by this paper
• Association of inflammatory score with all-cause and cardiovascular mortality in patients with metabolic syndrome: NHANES longitudinal cohort study

  2024cited by this paper
• Association between triglyceride-glucose related indices with the all-cause and cause-specific mortality among the population with metabolic syndrome

  2024cited by this paper
• Joint association of TyG index and high sensitivity C-reactive protein with cardiovascular disease: a national cohort study

  2024cited by this paper
• The interplay of factors in metabolic syndrome: understanding its roots and complexity

  2024cited by this paper
• The association of neutrophil-to-lymphocyte ratio with cardiovascular and all-cause mortality among the metabolic syndrome population

  2024cited by this paper
• Metabolic Syndrome: Updates on Pathophysiology and Management in 2021

  2022cited by this paper
• A Novel Inflammation and Insulin Resistance Related Indicator to Predict the Survival of Patients With Cancer

  2022cited by this paper
• Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis

  2022cited by this paper
• Adjusted Survival Curves Improve Understanding of Multivariable Cox Model Results.

  2021cited by this paper
• Pathophysiology of atherothrombosis: Mechanisms of thrombus formation on disrupted atherosclerotic plaques

  2020cited by this paper
• Modeling Adipogenesis: Current and Future Perspective

  2020cited by this paper
• From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.

  2016cited by this paper
• A clinical perspective of obesity, metabolic syndrome and cardiovascular disease

  2016cited by this paper
• Metabolic syndrome update.

  2016cited by this paper
• The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis.

  2010cited by this paper
• Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease.

  2006cited by this paper
• Metabolic syndrome.

  2005cited by this paper
• Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

  2005cited by this paper
• The insulin resistance syndrome: definition and dietary approaches to treatment.

  2005cited by this paper
• National Center for Health Statistics (NCHS)

  2005cited by this paper

• No citing papers are available for this paper.